HROW Harrow (HROW) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001360214
Cluster · 4 insidersC-suite buying · 2Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
123
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $404.6K priced
What the filings say about HROW
Insiders, 180 days
+$18.7K net bought
4 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$450.0K
1 notice
Harrow insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, HARROW, INC. insiders bought a net $18.7K of stock across 64 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Shojaei Amir sold about $450.0K of HROW on Aug 14, 2026; 123 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- 3 other insiders bought within 30 days.
- 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Graves Adrienne L bought about $31.1K of HROW on May 18, 2026; 3 other insiders bought within 30 days and 123 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- 3 other insiders bought within 30 days.
- 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SILVERNAIL LAUREN P bought about $31.0K of HROW on May 18, 2026; 3 other insiders bought within 30 days and 123 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Mar 22, 2024.
- +30.8% median (+27.3% mean) 90-day return after 4 previous buys.
- The trade is 0.3% of the 2,996,130 shares held after it.
- 3 other insiders bought within 30 days.
- 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER BAUM MARK L bought about $302.0K of HROW on May 14, 2026, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 123 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 22, 2022.
- The trade is 0.4% of the 814,679 shares held after it.
- 3 other insiders bought within 30 days.
- 123 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CFO BOLL ANDREW R. bought about $104.7K of HROW on May 14, 2026, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 123 funds added in the latest 13F quarter.64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$18.7K over 180 days
-$450.0K over 90 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
123 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
+36.4% year over year
more than 72% of Pharma & Biotech
Margin
-1.9% net margin
more than 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
25.8% of the float short (float per yahoo 2026-10-27) · 11.2 days to cover · settled 2026-10-15
more than 94% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders bought a net $18.7K while the stock fell 30% over six months, but 1 Form 144 notice ($450.0K) are queued to sell.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch HROW
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.8%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HROW: institutional holders (13F)
13F holdings, latest reported quarter
2,740,117 sh
$116.4M
2,400,000 sh
$101.9M
1,598,770 sh
$67.9M
1,417,212 sh
$60.2M
969,000 sh
$41.2M
Congress trades in HROW
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HROW planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
AMIR SHOJAEI
Filed 2026-08-21
$450.0K
HROW mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Private Capital Management Value Fund
$4.9M position · as of 2026-07-31
6.7%
Jacob Discovery Fund
$431.2K position · as of 2026-05-31
2.7%
Royce Smaller-Companies Growth Fund
$4.5M position · as of 2026-06-30
1.9%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$7.7M position · as of 2026-06-30
1.8%
PROFUND VP PHARMACEUTICALS
$201.6K position · as of 2026-06-30
1.8%
Buffalo Early Stage Growth Fund
$1.1M position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
1 active
3
Phase 4
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mark
Baum
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$23.6M
$33.1M
$3.6M
+614%
+20%
2024
$1.4M
$21.5M
$796.3K
+389%
-9%
2023
$15.3M
$3.1M
$6.5M
+63%
-8%
2022
$1.2M
$9.5M
$710.6K
+115%
-11%
2021
$7.3M
$8.7M
$3.0M
+26%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $18.7K bought by insiders over 180 days, 123 funds added last quarter, $450.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
HROW financials
Revenue growth
+36.4%
XBRL, annual
Net margin
-1.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$275.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HROW
| FY Dec 2025 | $272.3M |
| FY Dec 2024 | $199.6M |
| FY Dec 2023 | $130.2M |
| FY Dec 2022 | $88.6M |
| FY Dec 2021 | $72.5M |
| Jun 2026 | $70.7M |
| Mar 2026 | $44.2M |
| Dec 2025 | $89.1M |
| Sep 2025 | $71.6M |
| Jun 2025 | $63.7M |
| Mar 2025 | $47.8M |
| Dec 2024 | $66.8M |
| Sep 2024 | $49.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-13.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HROW
| FY Dec 2025 | -1.9% |
| FY Dec 2024 | -8.8% |
| FY Dec 2023 | -18.7% |
| FY Dec 2022 | -15.9% |
| FY Dec 2021 | -24.8% |
| Jun 2026 | -24.4% |
| Mar 2026 | -62.4% |
| Dec 2025 | +7.4% |
| Sep 2025 | +1.4% |
| Jun 2025 | +7.8% |
| Mar 2025 | -37.2% |
| Dec 2024 | +10.1% |
| Sep 2024 | -8.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$5.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HROW
| FY Dec 2025 | $43.0M |
| FY Dec 2024 | -$23.8M |
| FY Dec 2023 | $2.4M |
| FY Dec 2022 | -$892.0K |
| FY Dec 2021 | $3.3M |
| Jun 2026 | -$10.2M |
| Mar 2026 | -$9.2M |
| Dec 2025 | $8.1M |
| Sep 2025 | $16.4M |
| Jun 2025 | -$969.0K |
| Mar 2025 | $19.5M |
| Dec 2024 | -$18.3M |
| Sep 2024 | $2.3M |
At each fiscal year end
Single quarter
Debt to equity
19.74x
LongTermDebt as filed 2026-03-31 (includes the current portion); equity 2026-06-30
Debt to equity HROW
| FY Dec 2025 | 4.77x |
| FY Dec 2024 | 3.77x |
| FY Dec 2023 | 3.49x |
| FY Dec 2022 | 5.50x |
| FY Dec 2021 | 9.13x |
| Jun 2026 | 19.74x |
| Mar 2026 | 10.45x |
| Dec 2025 | 4.77x |
| Sep 2025 | 7.39x |
| Jun 2025 | 5.05x |
| Mar 2025 | 4.55x |
| Dec 2024 | 3.77x |
| Sep 2024 | 3.98x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.02x
TTM operating cash flow over LongTermDebt as filed 2026-03-31 (includes the current portion)
Cash flow to debt HROW
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | -0.08x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.05x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.05x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.05x |
| Jun 2025 | 0.02x |
| Mar 2025 | 0.01x |
| Dec 2024 | -0.08x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-114.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HROW
| FY Dec 2025 | -8.4% |
| FY Dec 2024 | -24.9% |
| FY Dec 2023 | -49.6% |
| FY Dec 2022 | -72.5% |
| FY Dec 2021 | -93.6% |
| Jun 2026 | -114.8% |
| Mar 2026 | -35.1% |
| Dec 2025 | -8.4% |
| Sep 2025 | -9.5% |
| Jun 2025 | -18.9% |
| Mar 2025 | -37.1% |
| Dec 2024 | -24.9% |
| Sep 2024 | -50.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-9.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HROW
| FY Dec 2025 | -1.3% |
| FY Dec 2024 | -5.0% |
| FY Dec 2023 | -10.4% |
| FY Dec 2022 | -11.0% |
| FY Dec 2021 | -23.1% |
| Jun 2026 | -9.8% |
| Mar 2026 | -3.8% |
| Dec 2025 | -1.3% |
| Sep 2025 | -1.4% |
| Jun 2025 | -3.1% |
| Mar 2025 | -6.6% |
| Dec 2024 | -5.0% |
| Sep 2024 | -10.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HROW
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HROW
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | +3.1% |
| FY Dec 2023 | +0.2% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +2.4% |
| Jun 2026 | -1.3% |
| Mar 2026 | +7.8% |
| Dec 2025 | +10.2% |
| Sep 2025 | +10.0% |
| Jun 2025 | +8.2% |
| Mar 2025 | +2.1% |
| Dec 2024 | +3.1% |
| Sep 2024 | -3.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HROW
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.3B
market value at close 2026-10-26 on 2026-08-06 shares, plus LongTermDebt as filed 2026-03-31 (includes the current portion), minus cash 2026-06-30
Enterprise value HROW
| FY Dec 2025 | $2.0B |
| FY Dec 2024 | $1.4B |
| FY Dec 2023 | $566.0M |
| FY Dec 2022 | $460.1M |
| FY Dec 2021 | $293.3M |
| Jun 2026 | $1.8B |
| Mar 2026 | $1.5B |
| Dec 2025 | $2.0B |
| Sep 2025 | $2.1B |
| Jun 2025 | $1.3B |
| Mar 2025 | $1.1B |
| Dec 2024 | $1.4B |
| Sep 2024 | $1.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield HROW
| FY Dec 2025 | +2.4% |
| FY Dec 2024 | -2.0% |
| FY Dec 2023 | +0.6% |
| FY Dec 2022 | -0.2% |
| FY Dec 2021 | +1.4% |
| Jun 2026 | +0.3% |
| Mar 2026 | +1.1% |
| Dec 2025 | +2.4% |
| Sep 2025 | +0.9% |
| Jun 2025 | +0.2% |
| Mar 2025 | +0.0% |
| Dec 2024 | -2.0% |
| Sep 2024 | +0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HROW
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M |
| Gross profit | $204.4M | $150.4M | $90.6M | $63.2M |
| Operating income | $30.5M | $8.8M | $431.0K | $1.9M |
| Net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M |
| EPS (diluted) | -0.14 | -0.49 | -0.75 | -0.51 |
| Operating cash flow | $43.9M | -$22.2M | $3.8M | $1.7M |
| Cash | $72.9M | $47.2M | $74.1M | $96.3M |
| Long-term debt | $250.0M | $262.7M | $246.7M | $151.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
HROW Stock Sonar score 6/7 axes
Find similar shapesCompareHROW ranks highest on insider conviction (80th percentile) and growth (72nd), and lowest on risk and compliance (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HROW filings, in plain words
Are Harrow insiders buying or selling HROW?
In the 180 days to 2026-10-28, Harrow insiders were net buyers, a net $18.7K: $468.7K of purchases and $450.0K of sales reported on Form 4, by 4 buyers and 1 seller.
Are there planned insider sales of HROW?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $450.0K of stock; the latest, by AMIR SHOJAEI, was filed 2026-08-21.
Read the full summary
In the 180 days to 2026-10-28, Harrow insiders were net buyers of HROW, a net $18.7K across purchases and sales reported on Form 4 by 4 buyers and 1 seller. 4 insiders reported purchases in that window. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $450.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
